561 related articles for article (PubMed ID: 9610728)
1. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis.
Jäger M; Benninger-Döring G; Prang N; Sylla BS; Laumbacher B; Wank R; Wolf H; Schwarzmann F
Int J Cancer; 1998 May; 76(5):694-701. PubMed ID: 9610728
[TBL] [Abstract][Full Text] [Related]
2. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
[TBL] [Abstract][Full Text] [Related]
3. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
Murray RJ; Wang D; Young LS; Wang F; Rowe M; Kieff E; Rickinson AB
J Virol; 1988 Oct; 62(10):3747-55. PubMed ID: 2843672
[TBL] [Abstract][Full Text] [Related]
5. Absence of Epstein-Barr virus-specific, HLA class II-restricted CD4+ cytotoxic T lymphocytes in infectious mononucleosis.
Enssle KH; Fleischer B
Clin Exp Immunol; 1990 Mar; 79(3):409-15. PubMed ID: 1690617
[TBL] [Abstract][Full Text] [Related]
6. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.
Gavioli R; De Campos-Lima PO; Kurilla MG; Kieff E; Klein G; Masucci MG
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5862-6. PubMed ID: 1321426
[TBL] [Abstract][Full Text] [Related]
7. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
[TBL] [Abstract][Full Text] [Related]
8. Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis.
Strang G; Rickinson AB
Eur J Immunol; 1987 Jul; 17(7):1007-13. PubMed ID: 2440688
[TBL] [Abstract][Full Text] [Related]
9. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
10. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
Levitsky V; Zhang QJ; Levitskaya J; Masucci MG
J Exp Med; 1996 Mar; 183(3):915-26. PubMed ID: 8642295
[TBL] [Abstract][Full Text] [Related]
11. HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1.
Stuber G; Dillner J; Modrow S; Wolf H; Székely L; Klein G; Klein E
Int Immunol; 1995 Apr; 7(4):653-63. PubMed ID: 7547693
[TBL] [Abstract][Full Text] [Related]
12. EBV-NK cells interactions and lymphoproliferative disorders.
Kanegane H; Yachie A; Miyawaki T; Tosato G
Leuk Lymphoma; 1998 May; 29(5-6):491-8. PubMed ID: 9643562
[TBL] [Abstract][Full Text] [Related]
13. X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency.
Sullivan JL; Byron KS; Brewster FE; Baker SM; Ochs HD
J Clin Invest; 1983 Jun; 71(6):1765-78. PubMed ID: 6306053
[TBL] [Abstract][Full Text] [Related]
14. Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.
Kerr BM; Kienzle N; Burrows JM; Cross S; Silins SL; Buck M; Benson EM; Coupar B; Moss DJ; Sculley TB
J Virol; 1996 Dec; 70(12):8858-64. PubMed ID: 8971014
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
Masucci MG; Torsteindottir S; Colombani J; Brautbar C; Klein E; Klein G
Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4567-71. PubMed ID: 3037521
[TBL] [Abstract][Full Text] [Related]
16. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
[TBL] [Abstract][Full Text] [Related]
17. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
Khanna R; Burrows SR; Moss DJ; Silins SL
J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
[TBL] [Abstract][Full Text] [Related]
18. Human cytotoxic T lymphocytes (CTL) against Epstein-Barr virus (EBV) infected cells: EBV specificity and involvement of major histocompatibility complex determinants in the lysis exerted by anti-EBV CTL toward HLA-compatible and allogeneic target cells.
Lakhdar M; Senik A; Fridman WH
Cell Immunol; 1984 Feb; 83(2):414-21. PubMed ID: 6198104
[TBL] [Abstract][Full Text] [Related]
19. Absence of allogeneic restriction in human T-cell-mediated cytotoxicity to Epstein-Barr virus-infected target cells. Demonstration of an HLA-linked control at the effector level.
Lipinski M; Fridman WH; Tursz T; Vincent C; Pious D; Fellous M
J Exp Med; 1979 Dec; 150(6):1310-22. PubMed ID: 229186
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.
Rasul AE; Nagy N; Sohlberg E; Ádori M; Claesson HE; Klein G; Klein E
J Immunol Methods; 2012 Nov; 385(1-2):60-70. PubMed ID: 22921685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
